AMP 105
Alternative Names: AMP-105Latest Information Update: 26 Mar 2026
At a glance
- Originator Nanjing Anji Biotechnology
- Developer Amphastar Pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer